Abstract：
OBJECTIVE: Dental implant treatment is considered contraindicated in patients with cancer on high-dose antiresorptive medication (HDAR). The aim of this prospective, feasibility study was to evaluate implant treatment in patients with cancer on HDAR, in terms of implant survival, implant success, and oral health-related quality of life (OHLQoL) after 2 years of loading.
METHODS: Implants were inserted in three groups of HDAR patients: (1) Previous tooth extraction, no medication-related osteonecrosis of the jaw (MRONJ), (2) Previous MRONJ, now healed, (3) Existing MRONJ, planned surgical resection. Implants were placed without adjunctive bone or soft tissue argumentation. Abutment operation was performed after ≥12 weeks. Prosthetic treatment was initiated ≥14 weeks. Survival and success rate were determined, and OHLQoL was analyzed with OHIP-49 and QLQ-H&N35 questionnaires. Patients were seen for 6 months, 1- and 2 years follow-up.
RESULTS: Twenty-two patients, 39 implants, completed the implant-based prosthetic treatment. Implant-supported crowns and overdentures were fabricated. Thirteen patients (59%) with 23 implants (59%) completed 2 years follow-up. Overall implant survival and success rate after 2 years of loading were 100% and 97.4%, respectively. OHLQoL for the patients increased in all groups after the treatment, a substantial increase was seen in group 3. Two patients developed MRONJ, but not related to the implant treatment.
CONCLUSIONS: Dental implant treatment, with high survival and success rate and increased post-treatment OHLQoL, is feasible in HDAR patients after 2 years of loading. Caution with general recommendations should be exercised.
METHODS: Implants were inserted in three groups of HDAR patients: (1) Previous tooth extraction, no medication-related osteonecrosis of the jaw (MRONJ), (2) Previous MRONJ, now healed, (3) Existing MRONJ, planned surgical resection. Implants were placed without adjunctive bone or soft tissue argumentation. Abutment operation was performed after ≥12 weeks. Prosthetic treatment was initiated ≥14 weeks. Survival and success rate were determined, and OHLQoL was analyzed with OHIP-49 and QLQ-H&N35 questionnaires. Patients were seen for 6 months, 1- and 2 years follow-up.
RESULTS: Twenty-two patients, 39 implants, completed the implant-based prosthetic treatment. Implant-supported crowns and overdentures were fabricated. Thirteen patients (59%) with 23 implants (59%) completed 2 years follow-up. Overall implant survival and success rate after 2 years of loading were 100% and 97.4%, respectively. OHLQoL for the patients increased in all groups after the treatment, a substantial increase was seen in group 3. Two patients developed MRONJ, but not related to the implant treatment.
CONCLUSIONS: Dental implant treatment, with high survival and success rate and increased post-treatment OHLQoL, is feasible in HDAR patients after 2 years of loading. Caution with general recommendations should be exercised.
摘要：
目的：对于使用大剂量抗再吸收药物（HDAR）的癌症患者，种植牙治疗被认为是禁忌的。这个前瞻性的目标，可行性研究是评估癌症患者在HDAR上的植入治疗，就植入物存活而言，植入成功,和口腔健康相关的生活质量（OHLQoL）后2年的负荷。
方法：在三组HDAR患者中插入植入物：（1）先前的拔牙，没有药物相关的颌骨坏死（MRONJ），（2）以前的MRONJ，现在痊愈了，(3)现有MRONJ，计划的手术切除。放置植入物时没有辅助骨或软组织论证。≥12周后行对接手术。修复治疗开始≥14周。确定生存率和成功率，用OHIP-49和QLQ-H&N35问卷分析OHLQoL。患者就诊6个月，1年和2年随访。
结果：22名患者，39个植入物，完成了基于植入物的假体治疗。制造了植入物支撑的牙冠和覆盖义齿。13例患者（59%）使用23个植入物（59%）完成了2年的随访。种植2年后的总生存率和成功率分别为100%和97.4%，分别。治疗后各组患者的OHLQoL均升高,在第3组中观察到大幅增加。两名患者发展为MRONJ，但与植入治疗无关。
结论：牙种植治疗，高生存率和成功率以及治疗后OHLQoL增加，在HDAR患者加载2年后是可行的。应谨慎对待一般性建议。
方法：在三组HDAR患者中插入植入物：（1）先前的拔牙，没有药物相关的颌骨坏死（MRONJ），（2）以前的MRONJ，现在痊愈了，(3)现有MRONJ，计划的手术切除。放置植入物时没有辅助骨或软组织论证。≥12周后行对接手术。修复治疗开始≥14周。确定生存率和成功率，用OHIP-49和QLQ-H&N35问卷分析OHLQoL。患者就诊6个月，1年和2年随访。
结果：22名患者，39个植入物，完成了基于植入物的假体治疗。制造了植入物支撑的牙冠和覆盖义齿。13例患者（59%）使用23个植入物（59%）完成了2年的随访。种植2年后的总生存率和成功率分别为100%和97.4%，分别。治疗后各组患者的OHLQoL均升高,在第3组中观察到大幅增加。两名患者发展为MRONJ，但与植入治疗无关。
结论：牙种植治疗，高生存率和成功率以及治疗后OHLQoL增加，在HDAR患者加载2年后是可行的。应谨慎对待一般性建议。
